COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01683955
Recruitment Status : Unknown
Verified February 2014 by Michael Laker, Henry Ford Health System.
Recruitment status was:  Recruiting
First Posted : September 12, 2012
Last Update Posted : February 25, 2014
Information provided by (Responsible Party):
Michael Laker, Henry Ford Health System

Brief Summary:
This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

Condition or disease Intervention/treatment Phase
Acute Blood Loss Anemia Osteoarthritis, Hip Drug: Transexamic Acid Drug: Placebo Phase 1

Detailed Description:
Autologous (donor) blood transfusion is an expensive and common occurrence after total hip replacement. There have been many proposed adjunctive measures to decrease intraoperative and postoperative blood loss during such surgery. Most of these include thrombin inhibition, so-called "minimally- invasive" techniques or instrumentation, or other adjunctive drugs. Hitherto, tranexamic acid, a specific drug that promotes part of the clotting cascade, has been used extensively in multiple areas of surgery with multiple studies evaluating its efficacy in cardiac surgery, spinal procedures, and as a dental swishing solution after tooth extraction. There have been small studies evaluating intravenous tranexamic acid and its effect on total hip replacements, with some promising results. The topical form of TA has been evaluated in only one prospective, randomized clinical trial with a significant decrease in postoperative blood loss and a trend towards decreased autologous blood transfusion rates. This study proposes to further evaluate tranexamic acid as an inexpensive and viable option for use in total hip arthroplasty. The topical form of the drug has been shown to achieve these hemostatic effects without increasing the risk of blood clots after surgery. A rigorous analysis of the effects of tranexamic acid demand a more standardized approach. Such a regimen is practiced at Henry Ford Hospital as all patients on the Adult Reconstruction service are placed on an identical dose of enoxaparin (a subcutaneous blood thinner) postoperatively for two weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 228 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty
Study Start Date : January 2013
Estimated Primary Completion Date : March 2014
Estimated Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Experimental: Tranexamic Acid
Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
Drug: Transexamic Acid
Topical tranexamic acid (2g/100mL 0.9% saline)
Other Name: cyclokapron

Placebo Comparator: Placebo
100mL 0.9% NS, applied topically
Drug: Placebo
100mL 0.9% sterile saline

Primary Outcome Measures :
  1. postoperative blood loss [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ]
    Preoperative and lowest postoperative hemoglobin

Secondary Outcome Measures :
  1. postoperative transfusion rate [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ]
    number of units transfused postoperatively

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All adult patients over age eighteen
  • Primary unilateral total hip arthroplasty at Henry Ford Hospital (Detroit, Michigan, United States) and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan, United States)

Exclusion Criteria:

  • patient history of venous thromboembolic disease or coagulopathy
  • use of anticoagulant medications within 7 days of surgery
  • history of arterial embolic disease
  • history of Class III or IV heart failure
  • renal failure
  • intraoperative cardiovascular, pulmonary, orthopaedic, or anesthetic complication (MI, intraoperative fracture, vasopressor support, emergent intubation).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01683955

Layout table for location contacts
Contact: Michael Laker, M.D. 248-514-8212
Contact: Trevor North, M.B.B.S. 248-904-8743

Layout table for location information
United States, Michigan
Henry Ford Hospital Not yet recruiting
Detroit, Michigan, United States, 48067
Contact: Michael Laker, M.D.    248-514-8212   
Contact: Trevor North, M.B.B.S    248-904-8743   
Principal Investigator: Michael W Laker, M.D.         
HFH Main campus Recruiting
Detroit, Michigan, United States, 48202
Contact: M Laker, MD    248-000-0000      
Contact: T North, MD    2489048743      
Sponsors and Collaborators
Henry Ford Health System
Layout table for investigator information
Principal Investigator: Michael Laker, M.D. Henry Ford Health Systems
Layout table for additonal information
Responsible Party: Michael Laker, Principal Investigator, Henry Ford Health System Identifier: NCT01683955    
Other Study ID Numbers: TEAHIPS
First Posted: September 12, 2012    Key Record Dates
Last Update Posted: February 25, 2014
Last Verified: February 2014
Keywords provided by Michael Laker, Henry Ford Health System:
Tranexamic Acid
Blood transfusion
Total hip arthroplasty
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Hip
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Pathologic Processes
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action